vTv Therapeutics to Present at the International Psychogeriatric Association International Congress
September 02 2016 - 7:00AM
Business Wire
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of new orally administered treatments for Alzheimer’s disease and
diabetes, today announced that company Chief Medical Officer
Dr. Larry Altstiel, MD, PhD will be giving a platform presentation
titled “Clinical Support for Advancement of the RAGE Antagonist
Azeliragon into Phase 3 Clinical Investigation for Mild Alzheimer’s
Disease” at the International Psychogeriatric Association
International Congress on Wednesday, September 7 between 10:00 and
11:30am.
The Phase 2b results of 5mg per day of azeliragon over a period
of 18 months showed statistically significant benefit in
mild-to-moderate Alzheimer’s patients (+3.1 points on ADAS-Cog11
standard measure of cognition) and greater benefit in mild patients
(+4.0 points on ADAS-Cog11), with improvements on secondary
endpoints including a statistically significant reduction in
psychiatric adverse events.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160902005083/en/
InvestorsIR@vtvtherapeutics.comorMediaPR@vtvtherapeutics.comorvTv
TherapeuticsNura Strong, 336-841-0300
X164nstrong@vTvTherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024